{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:50:21Z","timestamp":1776898221730,"version":"3.51.2"},"reference-count":200,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has undergone remarkable changes over the past 25 years. Small molecules (molecular weight of less than one kDa), together with newer immunotherapies that include monoclonal antibodies, antibody-drug conjugates, and most recently, chimeric antigen receptor (CAR) T-cells, have combined to double the disease\u2019s five-year survival rate to over 50% during the past few decades. Despite these advances, the disease is still considered incurable, and its treatment continues to pose substantial challenges, since therapeutic refractoriness and patient relapse are exceedingly common. This review focuses on the current pipeline, along with the contemporary roles and future prospects for small molecules in MM therapy. While small molecules offer prospective benefits in terms of oral bioavailability, cellular penetration, simplicity of preparation, and improved cost\u2013benefit considerations, they also pose problems of toxicity due to off-target effects. Highlighted in the discussion are recent developments in the applications of alkylating agents, immunomodulators, proteasome inhibitors, apoptosis inducers, kinesin spindle protein inhibitors, blockers of nuclear transport, and drugs that affect various kinases involved in intracellular signaling pathways. Molecular and cellular targets are described for each class of agents in relation to their roles as drivers of MM.<\/jats:p>","DOI":"10.3390\/ijms24032645","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T01:35:45Z","timestamp":1675128945000},"page":"2645","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-1926","authenticated-orcid":false,"given":"Hanley N.","family":"Abramson","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"ref_1","unstructured":"Loscalzo, J., Fauci, A., Kasper, D., Hauser, S., Longo, D., and Jameson, J.L. (2022). Harrison\u2019s Principles of Internal Medicine, McGraw-Hill Education. [21st ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, staging, and management of multiple myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN guidelines\u00ae insights: Multiple myeloma, version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-017-0368-z","article-title":"Current review on high-risk multiple myeloma","volume":"12","author":"Chan","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_8","unstructured":"National Cancer Institute (2020). SEER Cancer Statistics Review (CSR) 1975\u20132017: Myeloma."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.2021015220","article-title":"Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myeloma patients","volume":"140","author":"Yamamoto","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2022016958","article-title":"Cost-effectiveness: Maximizing impact by meticulous data","volume":"140","author":"Blommestein","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with sarcolysin in neoplastic diseases","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14065","article-title":"A novel alkylating agent melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells","volume":"174","author":"Ray","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1200\/JCO.20.03326","article-title":"Melflufen: A next-generation nitrogen mustard","volume":"39","author":"Holstein","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101528","DOI":"10.1016\/j.tranon.2022.101528","article-title":"Authors\u2019 reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA","volume":"25","author":"Schjesvold","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): A randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101374","DOI":"10.1016\/j.tranon.2022.101374","article-title":"The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA","volume":"18","author":"Olivier","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e941742","DOI":"10.4161\/21624011.2014.941742","article-title":"Lenalidomide induces degradation of IKZF1 and IKZF3","volume":"3","author":"Kronke","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Barankiewicz, J., Salomon-Perzy\u0144ski, A., Misiewicz-Krzemi\u0144ska, I., and Lech-Mara\u0144da, E. (2022). CRL4(CRBN) E3 ligase complex as a therapeutic target in multiple myeloma. Cancers, 14.","DOI":"10.3390\/cancers14184492"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"LaPlante, G., and Zhang, W. (2021). Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule Inhibitors. Cancers, 13.","DOI":"10.3390\/cancers13123079"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-cancerbio-051420-114114","article-title":"Small-molecule approaches to targeted protein degradation","volume":"5","author":"Faust","year":"2021","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): Outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation\u2014Lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137161","article-title":"Dose- and schedule-dependent immunomodulatory effects of the novel Celmod agent CC-92480 in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Wong","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/S2152-2650(21)02330-2","article-title":"EXCALIBER: A phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma","volume":"21","author":"Lonial","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","first-page":"86","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"44","author":"Weisel","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbamcr.2004.09.019","article-title":"Ubiquitin: Structures, functions, mechanisms","volume":"1695","author":"Pickart","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.2147\/OTT.S317570","article-title":"Efficacy and toxicity profile of carfilzomib-based regimens for treatment of newly diagnosed multiple myeloma: A systematic review","volume":"14","author":"Imtiaz","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1871529X21666210412113017","article-title":"Incidence and management of carfilzomib-induced cardiovascular toxicity; a systematic review and meta-analysis","volume":"21","author":"Latif","year":"2021","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.2959","article-title":"Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials","volume":"40","author":"Das","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/10428194.2018.1523398","article-title":"Ixazomib\u2014The first oral proteasome inhibitor","volume":"60","author":"Xie","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/fon.15.9","article-title":"The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma","volume":"11","author":"Richardson","year":"2015","journal-title":"Future Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): Final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2022-168091","article-title":"Phase I study of a novel oral proteasome inhibitor TQB3602 in relapsed\/refractory multiple myeloma","volume":"140","author":"Tang","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/01.HS9.0000846680.89917.3a","article-title":"Phase I study of TQB3602 capsule, an oral proteasome inhibitor, in relapsed refractory multiple myeloma","volume":"6","author":"Tang","year":"2022","journal-title":"Hemasphere"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","article-title":"Deubiquitinases in hematological malignancies","volume":"9","author":"Lei","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26979","DOI":"10.1038\/srep26979","article-title":"The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00280-018-3541-8","article-title":"Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases","volume":"81","author":"Ying","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-981-15-1025-0_18","article-title":"Targeting protein neddylation for cancer therapy","volume":"1217","author":"Zhou","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.apsb.2019.09.005","article-title":"Anticancer drug discovery by targeting cullin neddylation","volume":"10","author":"Yu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"dju083","DOI":"10.1093\/jnci\/dju083","article-title":"Overactivated neddylation pathway as a therapeutic target in lung cancer","volume":"106","author":"Li","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2834","DOI":"10.1038\/cddis.2017.195","article-title":"Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target","volume":"8","author":"Xie","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-11-0563","article-title":"Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma","volume":"11","author":"McMillin","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1111\/bcp.14078","article-title":"Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies","volume":"85","author":"Faessel","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1158\/1535-7163.MCT-18-0644","article-title":"TAS4464, a highly potent and selective inhibitor of NEDD8-activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models","volume":"18","author":"Yoshimura","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","article-title":"Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma","volume":"22","author":"Shah","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/BCJ20200170","article-title":"Combinations of histone post-translational modifications","volume":"478","author":"Taylor","year":"2021","journal-title":"Biochem. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41580-020-0262-8","article-title":"The roles of histone variants in fine-tuning chromatin organization and function","volume":"21","author":"Martire","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2741\/4847","article-title":"Epigenetic alterations in cancer","volume":"25","author":"Ilango","year":"2020","journal-title":"Front. Biosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., and Giorgi, F.M. (2020). Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes, 11.","DOI":"10.3390\/genes11050556"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Caprio, C., Sacco, A., Giustini, V., and Roccaro, A.M. (2020). Epigenetic aberrations in multiple myeloma. Cancers, 12.","DOI":"10.3390\/cancers12102996"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ruzic, D., Djokovi\u0107, N., Srdi\u0107-Raji\u0107, T., Echeverria, C., Nikolic, K., and Santibanez, J.F. (2022). Targeting histone deacetylases: Opportunities for cancer treatment and chemoprevention. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010209"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2019-129683","article-title":"Phase 1 study of bisthianostat, an orally efficacious pan-HDAC inhibitor: Part results of safety, pharmacokinetics and efficacy in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Huang","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41401-021-00728-y","article-title":"Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma","volume":"43","author":"Zhou","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/blood-2021-152390","article-title":"Phase 2 Suzhou MM02 study: Chidamide with VRD versus VRD in newly diagnosed high risk transplant eligible multiple myeloma patients","volume":"138","author":"Yao","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.13527","article-title":"Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma","volume":"171","author":"Sborov","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clml.2016.02.042","article-title":"VANTAGE 095: An international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma","volume":"16","author":"Siegel","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clml.2020.11.019","article-title":"Bortezomib, vorinostat, and dexamethasone combination therapy in relapsed myeloma: Results of the phase 2 MUK four trial","volume":"21","author":"Brown","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2020.07.013","article-title":"Phase 1 trial evaluating vorinostat plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma","volume":"20","author":"Kaufman","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.13517","article-title":"Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"171","author":"Vesole","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.3324\/haematol.2018.189969","article-title":"Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I\/II study for relapsed or refractory multiple myeloma (VERUMM study: Vorinostat in elderly, relapsed and unfit multiple myeloma)","volume":"103","author":"Waldschmidt","year":"2018","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V126.23.3040.3040","article-title":"ACY-241, a novel, HDAC6 selective inhibitor: Synergy with immunomodulatory (IMiD (R)) drugs in multiple myeloma (MM) cells and early clinical results (ACE-MM-200 study)","volume":"126","author":"Niesvizky","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood.V128.22.3307.3307","article-title":"Selective HDAC6 inhibitor ACY-241, an oral tablet, combined with pomalidomide and dexamethasone: Safety and efficacy of escalation and expansion cohorts in patients with relapsed or relapsed-and-refractory multiple myeloma (ACE-MM-200 study)","volume":"128","author":"Niesvizky","year":"2016","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"North, B.J., Almeciga-Pinto, I., Tamang, D., Yang, M., Jones, S.S., and Quayle, S.N. (2017). Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173507"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2019-129434","article-title":"Initial safety and efficacy of dose-escalating HDACs inhibitor chidamide with VRD (Chi-VRD) treatment for newly-diagnosed high-risk transplant eligible multiple myeloma patients","volume":"134","author":"Shang","year":"2019","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.febslet.2012.04.045","article-title":"The bromodomain interaction module","volume":"586","author":"Filippakopoulos","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"174523","DOI":"10.1016\/j.ejphar.2021.174523","article-title":"Bromodomains: A novel target for the anticancer therapy","volume":"911","author":"Gokani","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","article-title":"Bromodomains: Structure, function and pharmacology of inhibition","volume":"106","author":"Ferri","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \u201cundruggable\u201d MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1021\/cb4003283","article-title":"Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains","volume":"8","author":"Martin","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e21253","DOI":"10.7554\/eLife.21253","article-title":"Replication study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"6","author":"Aird","year":"2017","journal-title":"eLife"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1158\/1538-7445.AM2014-5531","article-title":"OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma","volume":"74","author":"Todaro","year":"2014","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials","volume":"59","author":"Albrecht","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-136392","article-title":"Open label, multicenter, dose-escalation\/ expansion phase Ib study to evaluate safety and activity of BET Inhibitor RO6870810 (RO), given as monotherapy to patients (pts) with advanced multiple myeloma","volume":"136","author":"Ramasamy","year":"2020","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood.V126.23.4255.4255","article-title":"Effect of the BET inhibitor, CPI-0610, alone and in combination with lenalidomide in multiple myeloma","volume":"126","author":"Siu","year":"2015","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Klener, P., Sovilj, D., Renesova, N., and Andera, L. (2021). BH3 mimetics in hematologic malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810157"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/acs.jmedchem.5b01888","article-title":"Expanding the cancer arsenal with targeted therapies: Disarmament of the anti-apoptotic Bcl-2 proteins by small-molecules","volume":"60","author":"Yap","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"104455","DOI":"10.1016\/j.compbiomed.2021.104455","article-title":"Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy","volume":"134","author":"Krishna","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2020.38.15_suppl.8509","article-title":"Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"38","author":"Kumar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"TPS8554","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8554","article-title":"A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma","volume":"38","author":"Mateos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood-2021-151631","article-title":"Trial in progress: Phase 1b\/2 open-label study of lisaftoclax (APG-2575) monotherapy or in combination with lenalidomide\/dexamethasone in patients with relapsed or refractory multiple myeloma (R\/R MM)","volume":"138","author":"Fu","year":"2021","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/1538-7445.AM2020-3077","article-title":"Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1182\/blood-2022-169666","article-title":"Preliminary safety of a Bcl-2 Inhibitor, Bgb-11417, in patients with relapsed\/refractory multiple myeloma harboring t(11,14): A non-randomized, open-label, phase 1b\/2 study","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1566524020666200929121016","article-title":"Peptide and small molecule inhibitors targeting myeloid cell leukemia 1 (Mcl-1) as novel antitumor agents","volume":"21","author":"Lu","year":"2021","journal-title":"Curr. Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1016\/j.clml.2019.09.081","article-title":"A phase 1, first-in-human study of AMG 176, a selective MCL-1 Inhibitor, in patients with relapsed or refractory multiple myeloma","volume":"19","author":"Spencer","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1158\/1538-7445.AM2019-4477","article-title":"MIK665\/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies","volume":"79","author":"Halilovic","year":"2019","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1538-7445.AM2021-983","article-title":"Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1","volume":"81","author":"Bhagwat","year":"2021","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-99-113504","article-title":"Preclinical activity of novel MCL1 inhibitor AZD5991 in multiple myeloma","volume":"132","author":"Matulis","year":"2018","journal-title":"Blood"},{"key":"ref_114","first-page":"870","article-title":"Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway","volume":"10","author":"Zhang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood-2019-128610","article-title":"Phase I Study of a novel Bcl-2 inhibitor, AT-101 in combination with lenalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"134","author":"Ailawadhi","year":"2019","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Parrondo, R.D., Paulus, A., and Ailawadhi, S. (2022). Updates in the Use of BCL-2-family small molecule inhibitors for the treatment of relapsed\/refractory multiple myeloma. Cancers, 14.","DOI":"10.3390\/cancers14143330"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2021-146043","article-title":"Safety and preliminary efficacy from the expansion cohort of a phase 1\/2 study of venetoclax plus daratumumab and dexamethasone vs daratumumab plus bortezomib and dexamethasone in patients with t(11;14) relapsed\/refractory multiple myeloma","volume":"138","author":"Kaufman","year":"2021","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2021-145757","article-title":"Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"Fso778","DOI":"10.2144\/fsoa-2021-0116","article-title":"Kinesin spindle protein inhibitors in cancer: From high throughput screening to novel therapeutic strategies","volume":"8","author":"Shahin","year":"2022","journal-title":"Future Sci. OA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood.V122.21.3167.3167","article-title":"ARRY-520 combined with pomalidomide displays enhanced anti-tumor activity in preclinical models of multiple myeloma","volume":"122","author":"Humphries","year":"2013","journal-title":"Blood"},{"key":"ref_125","first-page":"4373","article-title":"ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models","volume":"29","author":"Woessner","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.30892","article-title":"A phase 1 and 2 study of filanesib alone and in combination with low-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"123","author":"Shah","year":"2017","journal-title":"Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1002\/cncr.30174","article-title":"A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent\/refractory multiple myeloma","volume":"122","author":"Chari","year":"2016","journal-title":"Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cam4.4451","article-title":"Filanesib plus bortezomib and dexamethasone in relapsed\/refractory t(11;14) and 1q21 gain multiple myeloma","volume":"11","author":"Pan","year":"2022","journal-title":"Cancer Med."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Hanamura, I. (2021). Gain\/amplification of chromosome arm 1q21 in multiple myeloma. Cancers, 13.","DOI":"10.3390\/cancers13020256"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: Adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-019-0240-6","article-title":"A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"9","author":"Lee","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/bjh.16788","article-title":"Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: Safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib\/II Pomdefil clinical trial conducted by the Spanish MM group","volume":"192","author":"Ocio","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2257.2003.00492.x","article-title":"The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma","volume":"25","author":"Alexandrakis","year":"2003","journal-title":"Clin. Lab. Haematol."},{"key":"ref_135","first-page":"328","article-title":"Alpha 1-acid glycoprotein (AAG) is a potential patient selection biomarker for improved clinical activity of ARRY-520 in relapsed and refractory multiple myeloma (MM)","volume":"98","author":"Tunquist","year":"2013","journal-title":"Haematologica"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13543784.2020.1703179","article-title":"Filanesib for the treatment of multiple myeloma","volume":"29","author":"Algarin","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V126.23.728.728","article-title":"Phase 2 study of carfilzomib (CFZ) with or without filanesib (FIL) in patients with advanced multiple myeloma (MM)","volume":"126","author":"Zonder","year":"2015","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"TPS8613","DOI":"10.1200\/jco.2015.33.15_suppl.tps8613","article-title":"The AfFIRM study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma","volume":"33","author":"Lonial","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.abq4792","article-title":"Solving the nuclear pore puzzle","volume":"376","author":"Schwartz","year":"2022","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"a040691","DOI":"10.1101\/cshperspect.a040691","article-title":"Structure, maintenance, and regulation of nuclear pore complexes: The gatekeepers of the eukaryotic genome","volume":"14","author":"Raices","year":"2022","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1\u2014From biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1535-7163.MCT-15-0798","article-title":"Elevated translation initiation factor eIF4E Is an attractive therapeutic target in multiple myeloma","volume":"15","author":"Li","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","article-title":"Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region","volume":"96","author":"Kudo","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: First global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e2200147","DOI":"10.1200\/PO.22.00147","article-title":"A three-gene signature predicts response to selinexor in multiple myeloma","volume":"6","author":"Restrepo","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-021-01071-9","article-title":"Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","volume":"14","author":"Mateos","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1002\/ajh.26420","article-title":"A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma","volume":"97","author":"Cornell","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Tremblay, G., Daniele, P., Breeze, J., Li, L., Shah, J., Shacham, S., Kauffman, M., Engelhardt, M., Chari, A., and Nooka, A. (2021). Quality of life analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase 2b study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08453-9"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1016\/j.clml.2021.07.014","article-title":"Optimal supportive care with selinexor improves outcomes in patients with relapsed\/refractory multiple myeloma","volume":"21","author":"Chari","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1200\/JCO.2020.38.15_suppl.8510","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed\/refractory multiple myeloma (MM)","volume":"38","author":"Gasparetto","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1200\/JCO.2021.39.15_suppl.8038","article-title":"Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in carfilzomib nonrefractory multiple myeloma (MM) patients","volume":"39","author":"Gasparetto","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1158\/0008-5472.CAN-19-0677","article-title":"Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma","volume":"80","author":"Turner","year":"2020","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","article-title":"Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"86","author":"Jakubowiak","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_159","first-page":"E83","article-title":"Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study","volume":"97","author":"Delimpasi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ajh.26172","article-title":"Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma","volume":"96","author":"Auner","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2021.39.15_suppl.8018","article-title":"Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM)","volume":"39","author":"White","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1200\/JCO.2020.38.15_suppl.8530","article-title":"Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed\/refractory multiple myeloma (MM)","volume":"38","author":"Gasparetto","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2021-147725","article-title":"Selinexor in combination with daratumumab-bortezomib and dexamethasone for the treatment of relapse or refractory multiple myeloma: Initial results of the phase 2, open-label, multicenter GEM-Selibordara study","volume":"138","author":"Sureda","year":"2021","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"12613","DOI":"10.1182\/blood-2022-169053","article-title":"Preliminary results from the launch study-a multicenter, open-label study of selinexor, dexamethasone and chemotherapy drugs in relapsed\/refractory multiple myeloma","volume":"140","author":"Sun","year":"2022","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Qiu, L., Xia, Z., Fu, C., Chen, W., Chang, C., Fang, B., An, G., Wei, Y., Cai, Z., and Gao, S. (2022). Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): A phase II, single-arm study. BMC Med., 20.","DOI":"10.1186\/s12916-022-02305-4"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Ho, T., Tan, B.X., and Lane, D. (2019). How the other half lives: What p53 does when it is not being a transcription factor. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010013"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double hit events involving tumor suppressor genes underlie relapse from chemotherapy: Myeloma as a model","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1039\/C5AN01429H","article-title":"Identification of a p53-based portable degron based on the MDM2-p53 binding region","volume":"141","author":"Melvin","year":"2016","journal-title":"Analyst"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"a026047","DOI":"10.1101\/cshperspect.a026047","article-title":"The transactivation domains of the p53 protein","volume":"7","author":"Raj","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Herrero, A.B., Rojas, E.A., Misiewicz-Krzeminska, I., Krzeminski, P., and Gutierrez, N.C. (2016). Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122003"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1358\/dof.2022.47.4.3381587","article-title":"Navtemadlin","volume":"47","author":"Price","year":"2022","journal-title":"Drugs Future"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10637-019-00840-1","article-title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma","volume":"38","author":"Gluck","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00262-021-02908-5","article-title":"Bruton\u2019s tyrosine kinase: An emerging targeted therapy in myeloid cells within the tumor microenvironment","volume":"70","author":"Good","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"23769","DOI":"10.1074\/jbc.M112.372425","article-title":"Tyrosine kinase Btk is required for NK cell activation","volume":"287","author":"Bao","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","article-title":"T-cell expression of Bruton\u2019s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10428194.2013.794458","article-title":"Bruton\u2019s tyrosine kinase: Potential target in human multiple myeloma","volume":"55","author":"Liu","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.15058","article-title":"Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results","volume":"180","author":"Richardson","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13377","article-title":"A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"104","author":"Hajek","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2018-08-865659","article-title":"Ibrutinib and Aspergillus: A Btk-targeted risk","volume":"132","author":"Woyach","year":"2018","journal-title":"Blood"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hon.2723","article-title":"Final analysis of a phase 1\/2b study of ibrutinib combined with carfilzomib\/dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"38","author":"Chari","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hon.3012","article-title":"Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: Phase I trial results","volume":"40","author":"Ailawadhi","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2014.11.001","article-title":"Targeting the TGF\u03b2 pathway for cancer therapy","volume":"147","author":"Neuzillet","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF02989591","article-title":"Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma","volume":"15","author":"Kyrtsonis","year":"1998","journal-title":"Med. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2021.39.15_suppl.8039","article-title":"Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-beta signaling pathway","volume":"39","author":"Malek","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: Association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-135845","article-title":"Safety and preliminary efficacy results from a phase Ib\/II study of cobimetinib as a single agent and in combination with venetoclax with or without atezolizumab in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Schjesvold","year":"2020","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/j.clml.2014.06.004","article-title":"Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma","volume":"14","author":"Sharman","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hon.2353","article-title":"Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation","volume":"35","author":"Mey","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00070","article-title":"Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAF(V600) mutations: A cohort of the histology-independent VE-BASKET study","volume":"2","author":"Raje","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"819127","DOI":"10.3389\/fonc.2021.819127","article-title":"Where we stand with precision therapeutics in myeloma: Prosperity, promises, and pipedreams","volume":"11","author":"Pan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jha2.4","article-title":"Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib","volume":"1","author":"Richardson","year":"2020","journal-title":"eJHaem"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1182\/blood.V128.22.4526.4526","article-title":"Biomarker driven phase II clinical trial of trametinib in relapsed\/refractory multiple myeloma with sequential addition of the AKT inhibitor, GSK2141795 at time of disease progression to overcome treatment failure: A trial of the Princess Margaret phase II consortium","volume":"128","author":"Trudel","year":"2016","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14529","article-title":"m-TOR inhibitors and their potential role in haematological malignancies","volume":"177","author":"Calimeri","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2014.116269","article-title":"Activity of everolimus (RAD001) in relapsed and\/or refractory multiple myeloma: A phase I study","volume":"100","author":"Gunther","year":"2015","journal-title":"Haematologica"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2645\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:20:28Z","timestamp":1760120428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":200,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032645"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032645","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}